Medline is the largest provider of medical-surgical products and supply chain solutions in the US... Show more
MDLN represents Medline Inc., a healthcare company that supplies the everyday products hospitals, surgery centers, physician offices, and post-acute facilities rely on to deliver care. Although it operates largely behind the scenes, Medline is one of the most important names in medical distribution, providing everything from surgical kits and sterile procedure trays to wound care supplies, patient gowns, and personal protective equipment. Investors pay attention to Medline because of its scale, its vertically integrated manufacturing and distribution model, and its decades-long record of consistent growth in a relatively defensive industry.
Medline traces its roots to 1910, when A.L. Mills began selling aprons to Chicago butchers before expanding into medical gowns. His descendants, brothers Jim and Jon Mills, formally founded Medline in 1966 as a medical-surgical product manufacturer. The company was briefly public in the 1970s before returning to private family ownership for decades. In 2021, a consortium of private equity firms—including Blackstone, Carlyle, and Hellman & Friedman—acquired a majority stake in a leveraged buyout valued at roughly $34 billion, while the founding Mills family retained a significant ownership position.
In December 2025, Medline returned to the public markets, listing on the Nasdaq Global Select Market under the ticker MDLN. The IPO raised $6.26 billion, making it the largest public offering of 2025. The Mills family and the three private equity sponsors remain the company's principal stockholders.
Medline's business model combines manufacturing and distribution. Its Medline Brand segment offers approximately 190,000 products, many manufactured in its own facilities or sourced from global partners. Its Supply Chain Solutions segment offers roughly 145,000 third-party products and provides customized logistics and supply chain optimization services. In total, the company offers about 335,000 medical-surgical products across its 68 distribution facilities and a fleet of more than 2,000 trucks.
A key element of Medline's market position is its "Prime Vendor" model, under which it enters long-term agreements to act as the consolidated distributor for a customer's medical-surgical needs. These relationships provide visibility into customer demand and, as they mature, tend to shift purchasing toward Medline's own branded products. The company reported net sales of $25.5 billion for calendar year 2024, and $20.6 billion for the first nine months of 2025.
Investors follow MDLN primarily because of Medline's scale, its integrated business model, and its defensive, non-cyclical demand profile. Healthcare providers must continuously purchase medical supplies regardless of broader economic conditions, giving Medline a recurring revenue base. The company has grown net sales every year for more than 50 consecutive years at a CAGR of roughly 18%, a rare record of durability.
Medline's vertical integration is a competitive advantage. By manufacturing many of its own products while also distributing third-party goods, the company captures value across the supply chain and can offer customers cost savings and reliable service. Its ability to provide next-day delivery to 95% of its U.S. customers, supported by its own logistics network, reinforces customer loyalty and expands the scope of relationships over time.
The company also benefits from a large, fragmented market. Management has positioned Medline to gradually convert customers from third-party products to its own branded offerings, which generally carry higher margins. International expansion and continued penetration of the broader healthcare continuum of care represent further long-term growth drivers.
Despite its scale and stability, Medline faces several risks. The company carries a substantial debt load from its leveraged buyout, although proceeds from the IPO were used to reduce leverage. Higher interest rates and future refinancing needs could pressure its financial profile.
Medline is also exposed to macroeconomic and policy factors, including tariffs. In its registration statement, the company estimated tariff costs of $325 million to $375 million for fiscal 2025 and $150 million to $200 million for fiscal 2026. As a distributor of both its own and third-party products, Medline's margins can be sensitive to input costs and pricing pressure from large hospital customers.
Other considerations include intense competition from other distributors and manufacturers, potential supply chain disruptions, and the fact that the company does not currently plan to pay dividends. Investors should also weigh the concentration of ownership among the Mills family and private equity sponsors, which may influence governance and the future supply of shares available in the market.
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. It allows users to efficiently screen thousands of stocks and ETFs to surface ideas that align with their own investment strategies. Explore the AI Screener to build a watchlist tailored to your approach.
Medline is a distinctive company in the healthcare sector: a vertically integrated manufacturer and distributor that combines an enormous product catalog with a resilient, in-house logistics network. Its decades of uninterrupted growth, dominant position in medical-surgical distribution, and defensive end-market demand make its market position notable among publicly traded healthcare companies. As a relatively recent public company with strong private equity backing and a founding family still meaningfully invested, Medline remains a name worth understanding for investors evaluating the healthcare supply chain space.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry PharmaceuticalsOther